Sun Pharmaceutical Industries Limited (SUNPHARMA): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Sun Pharmaceutical Industries Limited, explained in plain English.
- Sun Pharmaceutical Industries Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- SUNPHARMA closed at ₹1,884.90 on 20 November 2026.
- Over the past year the shares are up 5.9%, trading between ₹1,583.70 and ₹2,046.90.
- Reported fundamentals show return on equity of 13.1%, a net margin of 17.79%, debt to equity of 3.62.
- Our Pulse grade checklist scores it C (58/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
- Annualised volatility over the past year is 19.73% with a maximum drawdown of -13.23% and a beta of 0.44 against NIFTY 50.
- Recent coverage: Why Sun Pharma Advanced Research shares surge 11% despite weak sentiments on D-Street; what's boosting medical stock?
- Recent coverage: Muhurat Trading 2026: Tata Steel, Sun Pharma, BSE among top gainers as Nifty 50, Sensex swing between gains and losses
- Recent coverage: Muhurat Trading 2026 Diwali Session Opening Bell: How Sensex, Nifty is performing on special day; check gainers, losers
Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma
Last traded values from 20 Nov 2026. Closed — weekend.
Pharma & Healthcare · Drug Manufacturers - Specialty & Generic
Sun Pharmaceutical Industries Limited (SUNPHARMA)
₹1,884.9
▼ 15.1 (-0.79%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Strong momentum · 4/51M
+8.14%
3M
-1.00%
6M
+0.24%
1Y
+6.05%
Where it sits in its 52-week range
72%Below 52-week high
5.8%
18.6% above the low
Momentum read
Strong
4/5 checks passed
52-wk high
₹2,001.1
52-wk low
₹1,589.3
Market cap
₹4,52,251 Cr
P/E (trailing)
41.2
Dividend yield
—
ROE
13.1%
Profit margin
17.79%
Revenue growth
11.9%
Price / Book
5.06
Debt / Equity
3.62
EPS (TTM)
45.7
Book value
₹372.65
Beta
0.44
Pulse grade: C, 58 out of 100
Momentum
B- ✓Trading above 50-day average
- ✓Trading above 200-day average
- ✓RSI in healthy 45-70 zone
- ✕Positive 3-month return
Growth
F- ✕Revenue growth above Pharma & Healthcare median (20.8%)
- ✓Revenue growing above 5%
- ✕Quarterly profits trending up
Profitability
C- ✕Return on equity above Pharma & Healthcare median (14.56%)
- ✓Return on equity above 12%
- ✓Profit margin above Pharma & Healthcare median (13.82%)
Safety
A- ✓Debt below Pharma & Healthcare median (18.57)
- ✓Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹16,100 crore · net profit ₹1,989 crore · margin 12.4%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
| Peer | Price ₹ | Day change | From 52-wk high |
|---|---|---|---|
| DRREDDY | 1,390.2 | -0.76% | -0.76% |
| CIPLA | 1,415 | -0.25% | -7.59% |
| DIVISLAB | 11,180.5 | +0.02% | -3.33% |
| APOLLOHOSP | 9,200 | +5.29% | 0.00% |
| LUPIN | 2,014 | +0.76% | -19.91% |
| AUROPHARMA | 1,799 | -0.37% | -3.03% |
SUNPHARMA headlines
No SUNPHARMA stories right now.
SUNPHARMA filings & announcements
SUNPHARMA, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
19.73%
Sharpe ratio
0.08
Sortino ratio
0.12
Max drawdown
-13.23%
Daily VaR (95%)
-1.89%
CAGR (1Y)
6.11%
Return skew
0.65
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.